New Drugs in Lipid Lowering Therapy

Over the past decades, treatment of lipid disorders has evolved significantly. This is not only limited to the management of hypercholesterolemia, but also hipertriglicerydemia, atherogenic dyslipidemia, and hiperlipoproteinemia(a). Moreover, the perspective seems to be even more encouraging. Based on the data from studies, in the next few years, we will have particles which might significantly improve the effectiveness and safeness of dyslipidemia therapy. With all those drugs, we may be able to individualize/personalize the therapy for concomitant conditions and diseases, such as diabetes, metabolic disturbances, NAFLD/MAFLD or statin intolerance.

Besides the drug availability, we may also have different approaches to optimize the therapy. For example, the combination of 2-3 drugs can be used for lipid-lowering therapy, more and more data has indicated that fixed-dose combination might significantly improve the therapy adherence and outcomes. These findings are important for patients with lipid disorders, as well as for the ongoing problem of statin non-adherence and patients’ non-compliance.

In light of these developments, we invite researchers within this field, to submit your review and research papers, to our Research Topic 'New Drugs in Lipid Lowering Therapy', Subtopics include but are not limited to:

Real-world evidence (RWE) data
New results on new lipid-lowering drugs (e.g., bempedoic acid, PCSK9 inhibitors, inclisiran, lomitapid, evinacumab) or drug combinations (FDC)
Attempts at therapy personalization.

Keywords: Lipid Lowering

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.